
The study quantified the incidence and risk factors for adverse drug events (ADEs) in 200 patients undergoing outpatient therapy with non-tuberculosis mycobacteria (NTM) infections. Fourteen percent of patients developed pre-specified ADEs, with the most common being thrombocytopenia (9%) and acute kidney injury (8%). Patients receiving aminoglycoside- or oxazolidinone-based therapies had a higher risk of ADEs. ADEs occurred early in treatment (median 25 days), with 35% discontinuing therapy due to ADEs.
Like
Save
Share